Opdivo (Nivolumab)

Nivolumab, the active ingredient in Opdivo, is a monoclonal antibody presented as a strength/form for intravenous use. It targets the PD-1 pathway and is employed in cancer immunotherapy for adult patients with specific malignant indications. GNH USA supplies Opdivo as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

GNH USA supplies Opdivo as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Opdivo is a PD‑1 checkpoint inhibitor used in several oncology indications.

- Melanoma: Improves survival and disease control in advanced or metastatic disease. - Non‑small cell lung cancer (NSCLC): Used as first‑line or subsequent therapy to extend progression‑free survival. - Renal cell carcinoma: Used in combination with ipilimumab to achieve durable responses. - Classical Hodgkin lymphoma: Provides durable remission in relapsed or refractory disease. - Head and neck squamous cell carcinoma (HSC S      ),   - UU